Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody

abstract

Multispecific proteins, such as bispecific antibodies (BsAbs), that bind to two different ligands are becoming increasingly important therapeutic agents. Such BsAbs can exhibit markedly increased target binding and target residence time when both pharmacophores bind simultaneously to their targets. The cross-arm binding efficiency (χ) describes an increase in apparent affinity when a BsAb binds to the second target or receptor (R2) following its binding to the first target or receptor (R1) on the same cell. χ is an intrinsic characteristic of a BsAb mostly related to the binding epitopes on R1 and R2. χ can have significant impacts on the binding to R2 for BsAbs targeting two receptors on the same cell. JNJ-61186372, a BsAb that targets epidermal growth factor receptor (EGFR) and c-Met, was used as the model compound for establishing a method to characterize χ. The χ for JNJ-61186372 was successfully determined via fitting of in vitro cell binding data to a ligand binding model that incorporated χ. The model-derived χ value was used to predict the binding of JNJ-61186372 to individual EGFR and c-Met receptors on tumor cell lines, and the results agreed well with the observed IC₅₀ for EGFR and c-Met phosphorylation inhibition by JNJ-61186372. Consistent with the model, JNJ-61186372 was shown to be more effective than the combination therapy of anti-EGFR and anti-c-Met monovalent antibodies at the same dose level in a mouse xenograft model. Our results showed that χ is an important characteristic of BsAbs, and should be considered for rationale design of BsAbs targeting two membrane bound targets on the same cell.

Keywords:

• Bispecific antibody
• c-Met
• cross-arm binding efficiency (χ)
• epidermal growth factor receptor
• mouse xenograft model
• pharmacokinetic/pharmacodynamic modeling
• quantitative flow cytometry
• receptor occupancy

Disclosure of potential conflict of interest

No potential conflicts of interest were disclosed.

Acknowledgment

The authors would like to thank Drs. Sylvie Laquerre and Donald Heald, employees of Janssen R&D, LLC, as well as Drs. Joost Neijssen and Aran Labrijn, employees of Genmab for their critical scientific reviews of this manuscript.

Funding

All authors are full time employees of Janssen R&D, LLC, which supported the study financially.